| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.45 | 53.21 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 11.82B | 44.08 | 25.05 | 18.49% | 29.63% | 31.37% | 5.36% | 0.09 |
| INBXInhibrx Biosciences, Inc. | 1.07B | 73.28 | 0.63 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.24B | 6.55 | -3.10 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.38B | 7.94 | -3.36 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 987.53M | 10.14 | -5.54 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.07B | 18.72 | -7.20 | 49.59% | -46.83% | -27.21% | 0.18 | |
| TNGXTango Therapeutics, Inc. | 1.41B | 10.44 | -8.77 | 15.17% | -151.15% | -62.81% | 0.18 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 6.67M | 7.95M | 7.5M | 9.09M | 12.81M | 7.13M | 2.19M | 1.8M | 200K |
| Revenue Growth % | - | 0.19% | -0.06% | 0.21% | 0.41% | -0.44% | -0.69% | -0.18% | -0.89% |
| Cost of Goods Sold | 16.99M | 25.51M | 33.45M | 47.91M | 73.5M | 2.69M | 110.19M | 1.19M | 2.29M |
| COGS % of Revenue | 2.55% | 3.21% | 4.46% | 5.27% | 5.74% | 0.38% | 50.27% | 0.66% | 11.43% |
| Gross Profit | -10.32M | -17.56M | -25.95M | -38.81M | -60.69M | 4.44M | -107.99M | 609K | -2.08M |
| Gross Margin % | -1.55% | -2.21% | -3.46% | -4.27% | -4.74% | 0.62% | -49.27% | 0.34% | -10.43% |
| Gross Profit Growth % | - | -0.7% | -0.48% | -0.5% | -0.56% | 1.07% | -25.34% | 1.01% | -4.42% |
| Operating Expenses | 18.56M | 27.68M | 37.01M | 52.81M | 80.25M | 12.34M | 21.12M | 219.83M | 329.36M |
| OpEx % of Revenue | 2.78% | 3.48% | 4.94% | 5.81% | 6.27% | 1.73% | 9.64% | 122.13% | 1646.82% |
| Selling, General & Admin | 1.57M | 2.61M | 4.65M | 9.02M | 6.84M | 12.36M | 21.12M | 29.38M | 127.91M |
| SG&A % of Revenue | 0.24% | 0.33% | 0.62% | 0.99% | 0.53% | 1.73% | 9.64% | 16.32% | 639.52% |
| Research & Development | 16.99M | 25.51M | 33.45M | 47.91M | 73.5M | 71.44M | 110.19M | 190.65M | 203.74M |
| R&D % of Revenue | 2.55% | 3.21% | 4.46% | 5.27% | 5.74% | 10.03% | 50.27% | 105.92% | 1018.72% |
| Other Operating Expenses | 0 | 24K | 68K | -4.12M | -80K | -71.45M | -110.19M | -199K | -2.29M |
| Operating Income | -12.15M | -19.73M | -29.51M | -43.71M | -67.44M | -76.56M | -129.12M | -219.22M | -331.45M |
| Operating Margin % | -1.82% | -2.48% | -3.94% | -4.81% | -5.27% | -10.75% | -58.9% | -121.79% | -1657.24% |
| Operating Income Growth % | - | -0.62% | -0.5% | -0.48% | -0.54% | -0.14% | -0.69% | -0.7% | -0.51% |
| EBITDA | -11.89M | -19.33M | -28.84M | -41.2M | -66.42M | -75.37M | -127.89M | -218.03M | -329.16M |
| EBITDA Margin % | -1.78% | -2.43% | -3.84% | -4.53% | -5.19% | -10.58% | -58.34% | -121.13% | -1645.82% |
| EBITDA Growth % | - | -0.63% | -0.49% | -0.43% | -0.61% | -0.13% | -0.7% | -0.7% | -0.51% |
| D&A (Non-Cash Add-back) | 253K | 399K | 676K | 2.52M | 1.02M | 1.2M | 1.23M | 1.19M | 2.29M |
| EBIT | -12.15M | -19.7M | -29.45M | -44.78M | -64.82M | -76.56M | -127.04M | -207.88M | 1.7B |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -19.92M | -2.55M |
| Interest Income | 759K | 0 | 0 | 5.72M | 10.82M | 5.22M | 16.11M | 11.92M | 10.94M |
| Interest Expense | 0 | 2.13M | 1.48M | 5.72M | 10.82M | 5.22M | 16.11M | 31.84M | 13.49M |
| Other Income/Expense | -739K | -2.1M | -1.41M | -6.79M | -8.19M | -5.2M | -16.11M | -20.5M | 2.02B |
| Pretax Income | -12.88M | -21.83M | -30.93M | -50.5M | -75.63M | -81.77M | -145.22M | -239.72M | 1.69B |
| Pretax Margin % | -1.93% | -2.75% | -4.12% | -5.55% | -5.91% | -11.48% | -66.25% | -133.18% | 8437.87% |
| Income Tax | -4.62M | 250K | 96K | 898K | 3K | 2K | 3K | 3K | 2K |
| Effective Tax Rate % | 0.64% | 0.89% | 1.01% | 1.02% | 1% | 1% | 1% | 1.01% | 1% |
| Net Income | -8.27M | -19.44M | -31.16M | -51.4M | -75.64M | -81.77M | -145.23M | -241.36M | 1.69B |
| Net Margin % | -1.24% | -2.45% | -4.16% | -5.65% | -5.91% | -11.48% | -66.25% | -134.09% | 8437.86% |
| Net Income Growth % | - | -1.35% | -0.6% | -0.65% | -0.47% | -0.08% | -0.78% | -0.66% | 7.99% |
| Net Income (Continuing) | -8.27M | -19.44M | -31.16M | -51.4M | -75.64M | -81.77M | -145.23M | -239.73M | 1.69B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 10.49M | 6.35M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.23 | -0.68 | -1.15 | -1.41 | -2.99 | -2.15 | -3.62 | -5.12 | 116.58 |
| EPS Growth % | - | -1.96% | -0.69% | -0.23% | -1.12% | 0.28% | -0.68% | -0.41% | 23.77% |
| EPS (Basic) | -0.23 | -0.68 | -1.15 | -1.41 | -2.99 | -2.15 | -3.62 | -5.12 | 116.58 |
| Diluted Shares Outstanding | 36.55M | 28.79M | 27.08M | 36.55M | 25.26M | 38.01M | 40.11M | 47.13M | 14.48M |
| Basic Shares Outstanding | 36.55M | 28.79M | 27.08M | 36.55M | 25.26M | 38.01M | 40.11M | 47.13M | 14.48M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 20.41M | 15.44M | 5.66M | 15.56M | 132.17M | 139.11M | 280.49M | 295.36M | 160.4M |
| Cash & Short-Term Investments | 20.02M | 13.47M | 2.1M | 11.54M | 128.66M | 131.3M | 273.87M | 277.92M | 152.6M |
| Cash Only | 20.02M | 13.47M | 2.1M | 11.54M | 128.66M | 131.3M | 273.87M | 277.92M | 152.6M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 696K | 690K | 438K | 615K | 878K | 257K | 778K | 420K |
| Days Sales Outstanding | - | 31.95 | 33.58 | 17.58 | 17.53 | 44.98 | 42.79 | 157.76 | 766.5 |
| Inventory | 0 | 999K | 2.31M | 3.21M | -129.28M | -878K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | 14.29 | 25.21 | 24.43 | - | - | - | - | - |
| Other Current Assets | 383K | 276K | 553K | 376K | 132.17M | 7.81M | 181K | 728K | 816K |
| Total Non-Current Assets | 864K | 1.8M | 4.33M | 10.93M | 11.57M | 11.34M | 10.38M | 12.54M | 20.37M |
| Property, Plant & Equipment | 864K | 1.8M | 2.59M | 10.68M | 11.32M | 9.49M | 7.22M | 9.37M | 13.54M |
| Fixed Asset Turnover | 7.72x | 4.40x | 2.89x | 0.85x | 1.13x | 0.75x | 0.30x | 0.19x | 0.01x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 1.73M | 245K | 245K | 1.85M | 3.16M | 3.16M | 6.83M |
| Total Assets | 21.27M | 17.25M | 9.98M | 26.49M | 143.74M | 150.45M | 290.88M | 307.89M | 180.77M |
| Asset Turnover | 0.31x | 0.46x | 0.75x | 0.34x | 0.09x | 0.05x | 0.01x | 0.01x | 0.00x |
| Asset Growth % | - | -0.19% | -0.42% | 1.65% | 4.43% | 0.05% | 0.93% | 0.06% | -0.41% |
| Total Current Liabilities | 5.28M | 8.92M | 16.18M | 20.57M | 31.4M | 22.45M | 27.58M | 56.31M | 40.73M |
| Accounts Payable | 167K | 775K | 6.53M | 3.12M | 13.46M | 9.13M | 8.33M | 10.95M | 9.24M |
| Days Payables Outstanding | 3.59 | 11.09 | 71.25 | 23.73 | 66.84 | 1.24K | 27.58 | 3.36K | 1.48K |
| Short-Term Debt | 4.26M | 5.17M | 5.93M | 4.67M | 1.5M | 1.67M | 1.86M | 0 | 1.59M |
| Deferred Revenue (Current) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 166K | 0 | 0 |
| Other Current Liabilities | 856K | 372K | 2.09M | 4.85M | 13.36M | 9.62M | 13.85M | 6.51M | 7.73M |
| Current Ratio | 3.87x | 1.73x | 0.35x | 0.76x | 4.21x | 6.20x | 10.17x | 5.25x | 3.94x |
| Quick Ratio | 3.87x | 1.62x | 0.21x | 0.60x | 8.33x | 6.23x | 10.17x | 5.25x | 3.94x |
| Cash Conversion Cycle | - | 35.16 | -12.45 | 18.28 | - | - | - | - | - |
| Total Non-Current Liabilities | 14.75M | 30.75M | 51.45M | 99.49M | 36.87M | 75.61M | 205.24M | 208.08M | 6.45M |
| Long-Term Debt | 14.66M | 9.49M | 3.56M | 37.06M | 35.95M | 70.47M | 202.07M | 206.97M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 3.17M | 1.11M | 6.45M |
| Deferred Tax Liabilities | 0 | 0 | 0 | -6.7M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 92K | 21.25M | 47.88M | 68.12M | 180K | 5.03M | 0 | 0 | 0 |
| Total Liabilities | 20.03M | 39.67M | 67.63M | 120.06M | 68.27M | 98.07M | 232.82M | 264.39M | 47.18M |
| Total Debt | 18.92M | 14.66M | 9.49M | 41.73M | 37.45M | 72.14M | 207.1M | 210.14M | 8.05M |
| Net Debt | -1.11M | 1.19M | 7.39M | 30.19M | -91.21M | -59.16M | -66.76M | -67.78M | -144.55M |
| Debt / Equity | 15.27x | - | - | - | 0.50x | 1.38x | 3.57x | 4.83x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -9.28x | -19.94x | -7.64x | -6.24x | -14.68x | -8.02x | -6.89x | -24.57x |
| Total Equity | 1.24M | -22.42M | -57.64M | -93.57M | 75.47M | 52.38M | 58.06M | 43.5M | 133.58M |
| Equity Growth % | - | -19.1% | -1.57% | -0.62% | 1.81% | -0.31% | 0.11% | -0.25% | 2.07% |
| Book Value per Share | 0.03 | -0.78 | -2.13 | -2.56 | 2.99 | 1.38 | 1.45 | 0.92 | 9.23 |
| Total Shareholders' Equity | -9.25M | -28.77M | -57.64M | -93.57M | 75.47M | 52.38M | 58.06M | 43.5M | 133.58M |
| Common Stock | 0 | 0 | 3K | 2K | 4K | 4K | 4K | 5K | 1K |
| Retained Earnings | -9.25M | -28.77M | -17.86M | -69.25M | -145.38M | -227.15M | -372.37M | -613.73M | -106.13M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -1.03M | -1.71M | -59.51M | -143.74M | -150.45M | 0 | 0 | 0 |
| Minority Interest | 10.49M | 6.35M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -18.11M | -18.75M | -23.09M | -32.08M | -47.97M | -80.32M | -115.3M | -193.31M | -194.41M |
| Operating CF Margin % | -2.72% | -2.36% | -3.08% | -3.53% | -3.75% | -11.27% | -52.6% | -107.39% | -972.04% |
| Operating CF Growth % | - | -0.04% | -0.23% | -0.39% | -0.5% | -0.67% | -0.44% | -0.68% | -0.01% |
| Net Income | -8.27M | -22.08M | -31.02M | -51.4M | -76.12M | -81.77M | -145.23M | -239.73M | 1.69B |
| Depreciation & Amortization | 253K | 399K | 676K | 1.16M | 1.02M | 1.2M | 1.23M | 1.19M | 2.29M |
| Stock-Based Compensation | 552K | 1.18M | 2.48M | 3.97M | 5.02M | 15.05M | 20.45M | 24.85M | 58.52M |
| Deferred Taxes | 0 | 0 | 0 | 1.08M | -2.14M | -9K | 0 | 0 | 0 |
| Other Non-Cash Items | -3.37M | 746K | 522K | 9.61M | 11.56M | 2.73M | 5.09M | 5.03M | -1.99B |
| Working Capital Changes | -6.28M | 999K | 4.25M | 3.48M | 12.69M | -17.52M | 3.16M | 15.35M | 52.05M |
| Change in Receivables | 0 | -140K | -550K | 491K | 117K | -167K | 130K | -521K | 381K |
| Change in Inventory | 0 | 1.09M | -672K | -2.47M | 7.76M | -11.03M | 0 | 0 | 0 |
| Change in Payables | 68K | 608K | 4.91M | -3.47M | 10.43M | -4.64M | -705K | 2.11M | 17.9M |
| Cash from Investing | -215K | -1.34M | -1.43M | -1.81M | -1.36M | -809K | -686K | -4.59M | -2.6M |
| Capital Expenditures | -215K | -1.34M | -1.43M | -1.81M | -1.36M | -864K | -686K | -4.59M | -2.6M |
| CapEx % of Revenue | 0.03% | 0.17% | 0.19% | 0.2% | 0.11% | 0.12% | 0.31% | 2.55% | 12.98% |
| Acquisitions | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 28.77M | 13.54M | 13.15M | 43.33M | 166.46M | 83.77M | 258.55M | 201.96M | 71.68M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | -1.38M | -828K | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - |
| Other Financing | 28.77M | 14.91M | 13.98M | 43.33M | 166.46M | 83.77M | 128.81M | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -18.32M | -20.09M | -24.52M | -33.89M | -49.33M | -81.19M | -115.99M | -197.9M | -197.01M |
| FCF Margin % | -2.75% | -2.53% | -3.27% | -3.73% | -3.85% | -11.39% | -52.91% | -109.95% | -985.03% |
| FCF Growth % | - | -0.1% | -0.22% | -0.38% | -0.46% | -0.65% | -0.43% | -0.71% | 0% |
| FCF per Share | -0.50 | -0.70 | -0.91 | -0.93 | -1.95 | -2.14 | -2.89 | -4.20 | -13.61 |
| FCF Conversion (FCF/Net Income) | 2.19x | 0.96x | 0.74x | 0.62x | 0.63x | 0.98x | 0.79x | 0.80x | -0.12x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26.72M | 11.51M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 4K | 3K | 2K |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -667.39% | - | - | - | -100.22% | -127.91% | -263% | -475.31% | 1905.92% |
| Return on Invested Capital (ROIC) | -6901.14% | - | - | - | - | - | - | - | - |
| Gross Margin | -154.87% | -220.88% | -346.05% | -426.86% | -473.82% | 62.27% | -4926.73% | 33.83% | -1042.5% |
| Net Margin | -124.03% | -244.55% | -415.51% | -565.27% | -590.54% | -1147.62% | -6625.27% | -13408.94% | 843786% |
| Debt / Equity | 15.27x | - | - | - | 0.50x | 1.38x | 3.57x | 4.83x | 0.06x |
| Interest Coverage | - | -9.28x | -19.94x | -7.64x | -6.24x | -14.68x | -8.02x | -6.89x | -24.57x |
| FCF Conversion | 2.19x | 0.96x | 0.74x | 0.62x | 0.63x | 0.98x | 0.79x | 0.80x | -0.12x |
| Revenue Growth | - | 19.24% | -5.66% | 21.24% | 40.86% | -44.37% | -69.24% | -17.88% | -88.89% |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| License, Non-Affiliate | 10.81M | - | 2.18M | 1.8M | 200K |
| License, Non-Affiliate Growth | - | - | - | -17.36% | -88.89% |
| Grant | - | 86K | 14K | - | - |
| Grant Growth | - | - | -83.72% | - | - |
| License, Affiliate - OX40 License Agreement | 2M | - | - | - | - |
| License, Affiliate - OX40 License Agreement Growth | - | - | - | - | - |
| License, Affiliate | 2M | - | - | - | - |
| License, Affiliate Growth | - | - | - | - | - |
| License, Affiliate - PD-L1 And 4-1BB License Agreement | - | - | - | - | - |
| License, Affiliate - PD-L1 And 4-1BB License Agreement Growth | - | - | - | - | - |
Inhibrx Biosciences, Inc. (INBX) has a price-to-earnings (P/E) ratio of 0.6x. This may indicate the stock is undervalued or faces growth challenges.
Inhibrx Biosciences, Inc. (INBX) reported $1.4M in revenue for fiscal year 2024. This represents a 79% decrease from $6.7M in 2016.
Inhibrx Biosciences, Inc. (INBX) saw revenue decline by 88.9% over the past year.
Inhibrx Biosciences, Inc. (INBX) reported a net loss of $155.1M for fiscal year 2024.
Inhibrx Biosciences, Inc. (INBX) has a return on equity (ROE) of 1905.9%. This is excellent, indicating efficient use of shareholder capital.
Inhibrx Biosciences, Inc. (INBX) had negative free cash flow of $143.4M in fiscal year 2024, likely due to heavy capital investments.